Hearing Loss
Jan 10, 2024
Ears to the Future: Evaluating Key Advancements and Trends Driving the Audiology Devices Market Growth
Audiology Devices have witnessed an unprecedented surge in demand in recent years. One of the primary drivers is the escalating prevalence of hearing impairments globally, attributed to various factors such as an aging population and increased exposure to environmental noise. As per the World Health Organization (W...
Read More...
Sep 07, 2023
Boston Scientific’s WATCHMAN FLX™ Pro; Quest Diagnostics’s AAV Test; Vitestro Started A.D.O.P.T. Clinical Trial; Signia Introduces Hearing Aids; Laborie Medical to Acquire Urotronic; Synchron’s Brain-Computer Interface Trial
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test On August 30, 2023, Quest Diagnostics announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the US Food and Drug Administration (FDA). The enzyme-linked immunosor...
Read More...
Mar 30, 2023
Mindray’s TE Air Handheld Ultrasound System; Getinge’s iCast™ Covered Stent System; Clinical Trial Update for the FLASH Proton Therapy for Cancers in the Bones; Gore’s Gore® Viafort Vascular Stent IVC Study; CoreLink’s Siber® Ti—3D Printed SI Joint Fusion System; USound and Partners’s Next-Generation Over-the-Counter Hearing Aids
TE Air Handheld Ultrasound System Launched by Mindray On March 16, 2023, Mindray, a China-based company announced the launch of TE Air, a high-quality, wireless, handheld, portable ultrasound device that is designed to easily fit into a pocket. Built with Mindray’s eWave platform and second-generation S...
Read More...
Nov 08, 2022
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma
Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Read More...
Sep 28, 2022
Evaluating the Growing Role of Devices in the Rehabilitation of Hearing Impairment
Hearing loss is a growing public health concern, and the number of cases is rising globally at a significant pace. As per the WHO, more than 1.5 billion people (nearly 20% of the global population) live with hearing loss, and 430 million of them have disabling hearing loss. According to the NIDCD, in the United Sta...
Read More...
Sep 27, 2022
Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec’s Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement
Daiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...
Read More...
Sep 15, 2022
Aerin Medical’s RhinAer Stylus; CE Mark for Haemonetics’s VASCADE Vascular Closure Device; J&J Vision Launches ACUVUE OASYS MAX 1-Day; Olympus Launches VISERA ELITE III Surgical Visualization Platform; GlucoRx’s Non-Invasive Glucose Monitoring Platform; Medtronic-BioIntelliSense’s Partnership; Corindus’s CorPath GRX Neurovascular System Trial; GE & Lantheus [18F]flurpiridaz PET Radiotracer Trial; Pulmonx’s AeriSeal System Trial; AtriAN’s Second Study on Cardioneuroablation
Johnson & Johnson Vision Launches New Contact Lens Innovation ACUVUE® OASYS MAX 1-Day for Meeting the Needs of Digitally Intense Lifestyles On September 12, 2022, Johnson & Johnson Vision, a part of Johnson & Johnson and a global leader in the eyecare market, had announced the launch of its newest in...
Read More...
Sep 01, 2022
Miracor Medical’s Picso Pivotal Study; Medtronic’s Extravascular ICD; Galaxy Medical’s CENTAURI Pulsed Electric Field System; UltraSight’s Novel Cardiac AI Technology; Oticon Launched the World’s Smallest Hearing Aid; Medtronic Completes Acquisition of Affera
FDA Approved IDE for Picso® Pivotal Study of Miracor Medical On August 23, 2022, Miracor Medical SA, a provider of innovative solutions for the treatment of severe cardiac diseases, announced that the FDA has approved an Investigational Device Exemption (IDE), allowing the company to begin a pivotal study with i...
Read More...
Oct 13, 2021
Analysing the Treatment Approaches in the Hearing Loss Market and Key Companies in the Domain
Hearing Loss is a severe condition that has a multifaceted impact on the individual’s growth and development. It can lead to isolation and loneliness and can also significantly reduce the quality of life. As per the WHO, nearly 430 million people (representing over 5% of the world’s population) require rehabilitati...
Read More...
May 21, 2021
Who is Going to be a Trendsetter in the Hereditary Deafness Market?
Hearing loss is observed to be the most common sensory disorder. Hearing loss is found to be an etiologically diverse condition that is accompanied by various disease-related complications and major clinical, social, and implications affecting the quality of life. Approximately 50% to 60% of hearing loss patients a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
